Finance - NBFC · Founded 1989 · www.healthxplatform.com · BSE 533259 · NSE HEALTHX · ISIN INE019J01013
No Notes Added Yet
Business
Health X Platform Ltd. is an Non-Banking Financial Company (NBFC) based in India. Its core business model revolves around providing financial services, primarily credit, to its target market. Given the company name "Health X Platform," it is likely specialized in financing the healthcare sector, which could include lending to hospitals, clinics, medical equipment manufacturers/purchasers, or potentially offering financial products related to healthcare services to consumers via a platform model. The company generates revenue predominantly through interest income from its loan portfolio, as well as fees for various financial services it provides.
Revenue Mix
Specific breakdowns of key business segments and their revenue contributions are not provided. However, based on the company name, potential lending segments could include:
Financing for healthcare infrastructure (e.g., hospital expansion, clinic setup).
Loans for medical equipment procurement.
Working capital finance for healthcare providers and pharmaceutical companies.
Potentially, consumer finance solutions for healthcare procedures or medical expenses, possibly facilitated through a digital platform.
Industry
The Indian NBFC sector is dynamic and highly competitive, characterized by a mix of large diversified players and specialized niche lenders. It acts as a crucial complement to the banking system, often catering to segments or customer profiles that traditional banks find less attractive or harder to serve. Health X Platform Ltd., with its implied focus on the healthcare sector, positions itself as a niche player within this competitive landscape. It likely competes with other specialized NBFCs focused on healthcare finance, as well as dedicated healthcare lending divisions of larger banks and diversified financial institutions. Its "Platform" aspect suggests a potential emphasis on digital distribution and efficient service delivery, aiming to differentiate through technology or specialized domain expertise.
MOAT
Without specific details, potential competitive advantages could include:
Niche Expertise: Deep understanding of the healthcare sector, its specific financial needs, and associated risks, allowing for better credit assessment and tailored product offerings.
Proprietary Platform: A robust, user-friendly, and efficient digital platform for origination, underwriting, and servicing loans could reduce operational costs, enhance customer experience, and enable wider reach.
Strategic Partnerships: Strong relationships with healthcare providers, medical equipment suppliers, or technology partners could provide a consistent deal flow and proprietary market access.
Data & Analytics: Leveraging data from its platform and healthcare sector focus to refine credit models and identify market opportunities.
Growth Drivers
Key factors that could drive growth for Health X Platform Ltd. over the next 3-5 years include:
Growth in the Indian Healthcare Sector: Increasing healthcare expenditure, demand for quality medical services, and government initiatives in healthcare infrastructure will drive demand for financing.
Digital Adoption: Further penetration and acceptance of digital lending platforms in India, allowing for efficient customer acquisition and service.
Underserved Market: Continued existence of healthcare-related financing gaps not fully met by traditional banks.
Expansion of Product Offerings: Introduction of new and innovative financial products catering to evolving needs within the healthcare ecosystem.
Ability to Raise Capital: Access to diverse funding sources at competitive rates to support balance sheet growth.
Risks
Credit Risk: Defaults on loans, particularly if the portfolio is concentrated in specific sub-segments of healthcare or regions, or due to macroeconomic downturns.
Liquidity Risk: Difficulty in accessing timely and cost-effective funding, which is critical for NBFC operations.
Interest Rate Risk: Mismatches between borrowing and lending rates, impacting net interest margins.
Regulatory Risk: Changes in RBI regulations for NBFCs, including capital adequacy norms, asset classification, and provisioning requirements, or specific regulations pertaining to healthcare financing.
Competition: Intense competition from banks, other NBFCs, and emerging FinTech players, potentially leading to margin pressure.
Technology and Cybersecurity Risk: Reliance on a digital platform exposes the company to risks of data breaches, system failures, and cyber-attacks.
Sector-Specific Risks: Policy changes in the healthcare industry, changes in insurance reimbursement models, or advancements in medical technology could impact the financial health of its borrowers.
Management & Ownership
Specific details on Health X Platform Ltd.'s promoters, management team, and ownership structure are not provided. Typically, for Indian NBFCs, strong promoter backing with a clear vision and an experienced management team with expertise in financial services, risk management, and the specific niche (healthcare in this case) are crucial. A well-governed board and diversified ownership structure, including institutional investors, often contribute to stability and growth.
Outlook
The outlook for Health X Platform Ltd. presents a balanced view. On the positive side, the robust growth trajectory of the Indian healthcare sector, coupled with the increasing adoption of digital financial services, provides a significant tailwind. A focused niche strategy, if executed with strong credit underwriting and an efficient digital platform, could allow the company to capture substantial market share within healthcare finance. However, challenges persist. The highly competitive NBFC landscape, the inherent credit risks associated with lending, the need for continuous access to capital, and potential regulatory shifts are significant headwinds. The company's ability to maintain asset quality, innovate its product offerings, and scale its platform while effectively managing operational and technological risks will be critical determinants of its long-term success.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Revenue | 307 | 270 | 274 | 281 | 286 | 298 | 301 | 346 | 374 | 447 |
| Other Income | 18 | 28 | 22 | -12 | 22 | 25 | 6 | 14 | 14 | 13 |
| Total Income | 325 | 298 | 296 | 269 | 307 | 324 | 307 | 359 | 388 | 460 |
| Total Expenditure | 317 | 273 | 278 | 305 | 311 | 292 | 324 | 356 | 399 | 455 |
| Operating Profit | 8 | 25 | 18 | -36 | -4 | 31 | -17 | 3 | -11 | 4 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit Before Tax | 5 | 25 | -174 | -39 | -5 | 30 | -19 | 1 | -15 | 2 |
| Provision for Tax | -29 | -25 | -23 | 1 | -22 | 4 | -3 | 1 | -2 | -0 |
| Profit After Tax | 34 | 50 | -151 | -40 | 18 | 27 | -15 | 0 | -13 | 2 |
| Adjustments | -18 | -19 | 41 | 13 | -4 | -3 | 3 | 1 | 2 | 1 |
| Profit After Adjustments | 16 | 31 | -109 | -27 | 14 | 24 | -13 | 1 | -11 | 3 |
| Adjusted Earnings Per Share | 5.2 | 9.8 | -34.4 | -8.5 | 4.3 | 7.5 | -4 | 0.4 | -3.5 | 0.8 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Revenue | 86 | 133 | 159 | 220 | 385 | 548 | 631 | 1040 | 1376 | 1111 | 1319 | 1468 |
| Other Income | 3 | 4 | 3 | 2 | 3 | 3 | 12 | 24 | 60 | 60 | 58 | 47 |
| Total Income | 89 | 137 | 162 | 222 | 389 | 552 | 643 | 1063 | 1436 | 1171 | 1378 | 1514 |
| Total Expenditure | 117 | 155 | 174 | 255 | 440 | 561 | 678 | 1083 | 1370 | 1167 | 1371 | 1534 |
| Operating Profit | -28 | -18 | -12 | -33 | -51 | -9 | -35 | -19 | 66 | 4 | 6 | -21 |
| Interest Expense | 1 | 3 | 1 | 3 | 1 | 3 | 3 | 2 | 1 | 0 | 1 | 1 |
| Depreciation | 7 | 7 | 6 | 6 | 5 | 4 | 4 | 8 | 9 | 6 | 7 | 7 |
| Profit Before Tax | -37 | -28 | -12 | -42 | -58 | -16 | 1109 | -122 | -30 | -204 | -2 | -31 |
| Provision for Tax | -0 | 1 | 2 | 1 | -5 | 1 | 244 | -23 | -36 | -70 | -1 | -4 |
| Profit After Tax | -37 | -29 | -15 | -43 | -52 | -17 | 865 | -99 | 6 | -134 | -1 | -26 |
| Adjustments | -0 | -0 | 3 | 5 | 13 | 7 | -238 | 27 | 3 | 42 | 3 | 7 |
| Profit After Adjustments | -37 | -29 | -12 | -38 | -39 | -10 | 627 | -72 | 9 | -91 | 1 | -20 |
| Adjusted Earnings Per Share | -11.5 | -9 | -3.7 | -11.8 | -12.2 | -3.3 | 197 | -22.7 | 2.8 | -28.7 | 0.4 | -6.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 19% | 8% | 19% | 31% |
| Operating Profit CAGR | 50% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -9% | -4% | -6% | 19% |
| ROE Average | -0% | -6% | 28% | 3% |
| ROCE Average | -0% | -11% | 33% | 7% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 218 | 195 | 175 | 143 | 210 | 200 | 827 | 753 | 762 | 670 | 641 |
| Minority's Interest | 0 | 0 | 28 | 58 | 36 | 29 | 268 | 240 | 237 | 195 | 124 |
| Borrowings | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liability | 31 | 49 | 29 | 25 | 69 | 63 | 70 | 120 | 77 | 98 | 155 |
| Other Liabilities & Provisions | 13 | 10 | 6 | 6 | 0 | 0 | 114 | 91 | 73 | 1 | 2 |
| Total Liabilities | 265 | 256 | 238 | 232 | 316 | 293 | 1278 | 1204 | 1149 | 963 | 922 |
| Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 9 | 9 |
| Investments | 9 | 9 | 18 | 22 | 41 | 30 | 513 | 443 | 385 | 265 | 414 |
| Fixed Assets | 126 | 125 | 117 | 116 | 114 | 110 | 93 | 104 | 108 | 100 | 114 |
| Other Loans | 22 | 13 | 5 | 10 | 10 | 6 | 11 | 15 | 2 | 7 | 10 |
| Other Non Current Assets | 19 | 1 | 1 | 1 | 0 | 0 | 120 | 98 | 64 | 17 | 11 |
| Current Assets | 89 | 108 | 97 | 83 | 151 | 146 | 540 | 541 | 580 | 563 | 361 |
| Total Assets | 265 | 256 | 238 | 232 | 316 | 293 | 1278 | 1204 | 1149 | 963 | 922 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 7 | 7 | 14 | 12 | 6 | 17 | 12 | 13 | 32 | 31 | 12 |
| Cash Flow from Operating Activities | -12 | -2 | -49 | -30 | -69 | -31 | -207 | -112 | 36 | -17 | -74 |
| Cash Flow from Investing Activities | -1 | 4 | 21 | -2 | -22 | 21 | 220 | 133 | -34 | -1 | 171 |
| Cash Flow from Financing Activities | 13 | 5 | 33 | 26 | 103 | 4 | -11 | -2 | -2 | -0 | -80 |
| Net Cash Inflow / Outflow | -0 | 7 | 5 | -6 | 11 | -5 | 1 | 19 | -0 | -19 | 18 |
| Closing Cash & Cash Equivalent | 7 | 14 | 12 | 6 | 17 | 12 | 13 | 32 | 31 | 12 | 30 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -11.51 | -9 | -3.73 | -11.81 | -12.2 | -3.27 | 197.04 | -22.7 | 2.79 | -28.66 | 0.37 |
| CEPS(Rs) | -9.2 | -6.81 | -2.89 | -11.6 | -14.85 | -3.97 | 273.26 | -28.69 | 4.71 | -40.15 | 1.62 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 68.52 | 59.6 | 55.15 | 43.23 | 64.48 | 61.27 | 258.25 | 235.27 | 238.09 | 210.58 | 201.47 |
| Net Profit Margin | -42.39 | -21.5 | -9.24 | -19.51 | -13.53 | -3.12 | 137.01 | -9.57 | 0.43 | -12.02 | -0.11 |
| Operating Margin | -41.11 | -18.84 | -7.23 | -17.64 | -14.56 | -2.51 | 176.24 | -11.57 | -2.14 | -18.31 | -0.1 |
| PBT Margin | -42.71 | -21.04 | -7.76 | -19 | -14.94 | -2.99 | 175.71 | -11.76 | -2.22 | -18.33 | -0.18 |
| ROA(%) | -12.92 | -10.97 | -5.96 | -18.25 | -19.05 | -5.62 | 110.18 | -8.02 | 0.5 | -12.64 | -0.15 |
| ROE(%) | -15.47 | -14.02 | -8.07 | -27.39 | -30.43 | -8.55 | 170.23 | -12.67 | 0.78 | -18.71 | -0.22 |
| ROCE(%) | -14.29 | -11.07 | -5.71 | -23.5 | -31.37 | -6.48 | 214.79 | -15.23 | -3.88 | -28.4 | -0.21 |
| Price/Earnings(x) | 0 | 0 | 0 | 0 | 0 | 0 | 1.81 | 0 | 108.6 | 0 | 706.65 |
| Price/Book(x) | 0.94 | 1.66 | 2.01 | 2.77 | 0.97 | 1.9 | 1.38 | 0.94 | 1.27 | 1.15 | 1.3 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 2.45 | 2.31 | 2.21 | 1.7 | 0.48 | 0.67 | 1.46 | 0.49 | 0.67 | 0.68 | 0.62 |
| EV/Core EBITDA(x) | -7.5 | -16.96 | -28.2 | -11.39 | -3.6 | -39.61 | -26.08 | -26.24 | 13.93 | 195.23 | 129.51 |
| Interest Earned Growth(%) | 78.39 | 54.08 | 19.91 | 37.9 | 75.41 | 42.23 | 15.18 | 64.68 | 32.3 | -19.25 | 18.75 |
| Net Profit Growth | -146.59 | 21.83 | 48.45 | -191 | -21.63 | 67.21 | 5161.5 | -111.5 | 105.88 | -2381.77 | 98.92 |
| EPS Growth(%) | -145.63 | 21.81 | 58.5 | -216.12 | -3.29 | 73.19 | 6126.54 | -111.52 | 112.3 | -1126.34 | 101.29 |
| Interest Coverage(x) % | -25.73 | -8.58 | -13.69 | -13.01 | -38.31 | -5.27 | 333.22 | -62.15 | -27.52 | -694.1 | -1.4 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.92 | 73.92 | 73.92 | 73.94 | 74.11 | 74.24 | 74.24 | 74.69 | 74.84 | 74.07 |
| FII | 0.56 | 0.61 | 0.99 | 1.71 | 1.6 | 1.88 | 2.04 | 2.25 | 2.17 | 2.29 |
| DII | 0.96 | 1.35 | 1.98 | 1.85 | 2.06 | 2.09 | 2.07 | 2.07 | 2.6 | 2.6 |
| Public | 24.56 | 24.12 | 23.11 | 22.5 | 22.22 | 21.79 | 21.65 | 20.99 | 20.39 | 21.04 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.35 | 2.35 | 2.35 | 2.35 | 2.36 | 2.36 | 2.36 | 2.38 | 2.38 | 2.36 |
| FII | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 |
| DII | 0.03 | 0.04 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 |
| Public | 0.78 | 0.77 | 0.74 | 0.72 | 0.71 | 0.69 | 0.69 | 0.67 | 0.65 | 0.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +19% | +8% | +19% | +31% |
| Operating Profit CAGR | +50% | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | -9% | -4% | -6% | +19% |
| ROE Average | 0% | -6% | +28% | +3% |
| ROCE Average | 0% | -11% | +33% | +7% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.92 | 73.92 | 73.92 | 73.94 | 74.11 | 74.24 | 74.24 | 74.69 | 74.84 | 74.07 |
| FII | 0.56 | 0.61 | 0.99 | 1.71 | 1.6 | 1.88 | 2.04 | 2.25 | 2.17 | 2.29 |
| DII | 0.96 | 1.35 | 1.98 | 1.85 | 2.06 | 2.09 | 2.07 | 2.07 | 2.6 | 2.6 |
| Public | 24.56 | 24.12 | 23.11 | 22.5 | 22.22 | 21.79 | 21.65 | 20.99 | 20.39 | 21.04 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.35 | 2.35 | 2.35 | 2.35 | 2.36 | 2.36 | 2.36 | 2.38 | 2.38 | 2.36 |
| FII | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 |
| DII | 0.03 | 0.04 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 |
| Public | 0.78 | 0.77 | 0.74 | 0.72 | 0.71 | 0.69 | 0.69 | 0.67 | 0.65 | 0.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.